Autologous Volar Fibroblast Injection Into the Stump Site of Amputees

Inclusion Criteria: Patients interested in study participation must meet all of the following inclusion criteria: * May be male or female * Must be between 18 years and 65 years of age * Must have a below the knee amputation. * Must be using a prosthetic for the vicinity of 3 months or have had osteo-integration of a prosthetic in place for 1 month. * In the opinion of the investigator, must be medically able to undergo the administration of study material determined by laboratory tests obtained within 7 days before baseline for which the investigator identified no clinically significant abnormality. * Be able to comprehend the informed consent document and provide consent for participation * Females of childbearing potential must: * have a negative pregnancy test at screening * agree to not become pregnant or breastfeed for the period of the study through 1 month after completion of the study * be willing to use a reliable form of contraception during the study * Be willing and able to comply with the scheduled visits, biopsy/injection procedures, wound care instructions treatment plan, and other study procedures for the duration of the study. Exclusion Criteria: Patients meeting any of the following criteria will be ineligible for study participation: * A skin erosion deeper than the skin dermis. * Having received any investigational drug within 30 days prior to study entry * An allergy history to any study materials including local anesthetic, dimethyl sulfoxide, human albumin, or bovine constituents, hetastarch, or EMLA (lidocaine 2.5% and prilocaine 2.5%). * Pregnant, lactating, or trying to become pregnant * A history of keloid formation * Having a significant medical history that the investigator feels is not safe for study participation (for example, some forms of autoimmune conditions, metastatic cancer, infectious diseases such as HIV, HTLV I/II, Hepatitis B, Hepatitis C). Biopsies taken from individuals with infections that are not allowed to enter the cell therapy core will make it such that these individuals cannot participate. * Specifically we will exclude those with autoimmune diseases affecting the skin such as lupus. * Presence of necrotic ischemic tissue on any stump ulcers, and/or capillary refill on stump skin of greater than 3 seconds * Active infection of the residual limb. * Active smoker during the study * We will also exclude those who are on chronic immunosuppressive therapies such as oral steroids, but also those on chronic topical steroids in the area of investigation. * Recent amputee who has not yet been approved to use a prosthetic. * Use of a prosthetic for less than 3 months. * Amputees with neuromas of the terminal limb within the last 3 months. * Known bleeding disorder. * For those receiving Bellafill/collagen skin test: history of serious allergy, such as anaphylaxis. * For whole stump injections: Have a history of congenital or idiopathic methemoglobinemia, glucose-6-phosphate deficiencies, or use of medications associated with drug-induced methemoglobinemia. (specifically: Sulfonamides, Acetaminophen, Acetanilid, Aniline dyes, Benzocaine, Chloroquine, Dapsone, Naphthalene, Nitrates and Nitrites, Nitrofurantoin, Nitroglycerin, Nitroprusside, Pamaquine, Para-aminosalicylic acid, Phenacetin, Phenobarbital, Phenytoin, Primaquine, or Quinine.)